View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry

Blog

DPharm Makes Stuff Happen!


  • April 30, 2015

  • 330_24529_full-800w

    Jeff Kasher, formerly vice president of Clinical Innovation and Implementation at Eli Lilly and president of Patients Can’t Wait with Pablo Gravier, CEO, TrialReach at the inaugural DPharm Europe

    We are so pleased to see another exciting outcome from the DPharm conference. Congratulations to TrialReach on making news in Forbes from their work with industry in registering patients in trials faster.

    Drug Companies Pin Hopes On TrialReach To Enroll Patients In Clinical Trials Faster

    Two years ago, Pfizer, Novartis, and Eli Lilly set aside competition to form a consortium called Patients to Trials. Goal: To solve an issue that has bedeviled their industry and slowed drug development—namely how to enroll patients in clinical trials faster. According to CenterWatch, 75% of the public is unaware of clinical studies, and nearly half of trials don’t fulfill their recruitment goals, causing delays. “If we can compress the time it takes to enroll a trial, we can get medicines to patients much faster,” says Jeff Kasher, formerly vice president of Clinical Innovation and Implementation at Eli Lilly, and president of Patients Can’t Wait.

    Continue Reading here: http://www.forbes.com/sites/zinamoukheiber/2015/04/23/drug-companies-pin-hopes-on-trialreach-to-enroll-patients-in-clinical-trials-faster/